Nexvet expands veterinary biologics research team
Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team.
CSL’s former director of preclinical cell biology, Dr Samantha Busfield, and former director of analytical biochemistry, Dr Dallas Hartman, have both joined Nexvet’s veterinary biologics research centre in Melbourne.
The centre is designed to bolster Nexvet’s product pipelines and support the company’s existing veterinary drug programs. Nexvet specialises in species-specific biologic treatments for companion animals, produced with its PETization platform.
“I’m delighted to welcome two such experienced research managers to the Nexvet team,” Nexvet chief science officer Dr David Gearing commented. “Their breadth of experience in research and development in biopharmaceuticals will be invaluable.”
He said Nexvet is putting together a team of scientists with diverse biopharma backgrounds for its research activities.
“We are excited about our work on new animal therapies, building on our pioneering research in this field to build a world-class centre for veterinary biologics research,” Gearing said.
In April, Nexvet raised US$31.5 million ($34.9 million) to fund clinical programs for treatment candidates for canine pain, feline pain and canine inflammation.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
